Vaccinex Completes Last Patient Visit In Randomized, SIGNAL-AD Phase 1b/2 Study Of Pepinemab Treatment For Alzheimer's Disease
Portfolio Pulse from Benzinga Newsdesk
Vaccinex has completed the last patient visit in its randomized, SIGNAL-AD Phase 1b/2 study of Pepinemab treatment for Alzheimer's Disease.
June 06, 2024 | 12:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vaccinex has completed the last patient visit in its SIGNAL-AD Phase 1b/2 study of Pepinemab for Alzheimer's Disease, marking a significant milestone in the development of this treatment.
The completion of the last patient visit in a clinical trial is a critical milestone, indicating that the study is progressing as planned. This could positively impact Vaccinex's stock price as it shows advancement in their Alzheimer's treatment pipeline.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100